|
N
|
397
|
255
|
121
|
45
|
818
|
265
|
|
Age
|
53.2 (12.5)
|
54.0 (12.3)
|
53.8 (12.4)
|
56.2 (11.2)
|
53.7 (12.3)
|
57.4 (10.3)
|
|
Female (%)
|
79.1
|
71.0
|
85.1
|
73.3
|
76.6
|
83.8
|
|
Disease duration (years), median (IQR)
|
10 (6–18)
|
9 (5–14)
|
12 (7–19)
|
13 (7–21)
|
10 (6–17)
|
9 (5–17)
|
|
Rheumatoid factor positive (%)
|
82.1
|
83.5
|
84.3
|
77.8
|
82.2
|
77.7
|
|
Swollen joint count
|
10.2 (6.2)
|
11.3 (6.4)
|
9.6. (6.4)
|
10.9 (6.6)
|
10.5 (6.3)
|
8.2 (5.3)
|
|
Tender joint count
|
13.0 (7.3)
|
13.0 (7.4)
|
12.3 (7.4)
|
13.6 (7.3)
|
12.9 (7.3)
|
10.5 (6.9)
|
|
ESR (mm/h), median (IQR)
|
33 (20–54)
|
32 (18–54)
|
30 (17–44)
|
36 (22–51)
|
32 (18–53)
|
23 (14–37)
|
|
CRP (mg/l), median (IQR)
|
20 (7–42)
|
18 (7–48)
|
18 (7–32)
|
21 (6–36)
|
18 (7–42)
|
12 (4–27)
|
|
DAS28
|
6.1 (1.1)
|
6.2 (1.2)
|
5.9 (1.2)
|
6.3 (1.0)
|
6.1 (1.1)
|
5.5 (1.1)
|
|
FFbH
|
53.4 (22.9)
|
52.8 (20.9)
|
53.2 (25.1)
|
52.7 (23.3)
|
53.1 (22.8)
|
61.4 (22.4)
|
|
Number of previous DMARDs
|
3.9 (1.3)
|
3.9 (1.4)
|
4.4 (1.3)
|
4.3 (1.6)
|
4.0 (1.4)
|
2.8 (0.9)
|
|
Current treatment DMARD (%)
| | | | | | |
|
MTX alone
|
33.0
|
67.5
|
43.0
|
60.0
|
46.7
|
1.5
|
|
Other single DMARD
|
11.9
|
14.5
|
8.3
|
8.8
|
12.0
|
29.8
|
|
Combination of two DMARDs
|
5.3
|
8.6
|
5.8
|
4.4
|
6.4
|
57.3
|
|
Combinations of three DMARDs
|
1.3
|
1.6
|
1.6
|
0.0
|
1.3
|
11.3
|
|
No DMARD
|
48.6
|
7.8
|
41.3
|
26.7
|
33.6
|
0
|
|
Biologic dose/week (mg)a
|
49.7 (4.1)
|
4.0 (1.9)
|
21.5 (7.0)
|
700 (0)
|
-
|
-
|
|
Comorbidity (%)
|
72.6
|
68.5
|
64.5
|
71.1
|
70.0
|
72.8
|
|
Osteoporosis (%)
|
30.2
|
27.9
|
22.3
|
35.6
|
28.6
|
18.5
|
